Stockholm Ischemic Heart Disease Study
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
Overview
The Stockholm Ischemic Heart Disease study is a randomized open label trial that assessed the effect of clofibrate and nicotinic acid vs placebo on ischemic heart disease mortality.
Study Description
Study Description
| Study Description | |
| Study Design | |
| Allocation | Randomized |
| Endpoint | Ischemic heart disease mortality |
| Masking | Open label |
| Study Details | |
| Primary Purpose | |
| Condition | Survivors of a myocardial infarction |
| Study Arms | Clofibrate and nicotinic acid Control |
| Population Size | 555 subjects |
Publications
Publications
The Stockholm Ischemic Heart Disease study revealed a 36% decrease in ischemic heart disease mortality among patients who received the treatment vs control. The treatment effect on ischemic heart disease mortality was mostly related to the triglycerides plasma concentration, particularly among patients with a triglyceride plasma concentration higher than 1.5 mmol/l and those who had a decrease in the serum triglyceride by at least 30%.[1]
References
References
- ↑ Carlson LA, Rosenhamer G (1988). “Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid”. Acta Med Scand. 223 (5): 405–18. PMID 3287837.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH